Cancer Therapy

You have full text access to this OnlineOpen article

Identification of potential pharmacogenomic markers of clinical efficacy of 5-fluorouracil in colorectal cancer

  1. Stefania Nobili1,
  2. Cristina Napoli1,
  3. Ida Landini1,
  4. Maria Morganti1,
  5. Fabio Cianchi2,
  6. Rosa Valanzano3,
  7. Francesco Tonelli3,
  8. Camillo Cortesini2,
  9. Teresita Mazzei1,
  10. Enrico Mini1,†,*

Article first published online: 17 JUN 2010

DOI: 10.1002/ijc.25514

Issue

International Journal of Cancer

International Journal of Cancer

Volume 128, Issue 8, pages 1935–1945, 15 April 2011

Additional Information

How to Cite

Nobili, S., Napoli, C., Landini, I., Morganti, M., Cianchi, F., Valanzano, R., Tonelli, F., Cortesini, C., Mazzei, T. and Mini, E. (2011), Identification of potential pharmacogenomic markers of clinical efficacy of 5-fluorouracil in colorectal cancer. Int. J. Cancer, 128: 1935–1945. doi: 10.1002/ijc.25514

Author Information

  1. 1

    Department of Pharmacology, University of Florence, Florence, Italy

  2. 2

    Department of Medical and Surgical Critical Care, University of Florence, Florence, Italy

  3. 3

    Department of Clinical Pathophysiology, University of Florence, Florence, Italy

  1. †

    Tel: +39-055-4271305, Fax: +39-055-4271280

*Department of Pharmacology, University of Florence, viale Pieraccini, 6 - 50139 Firenze, Italy

Publication History

  1. Issue published online: 22 FEB 2011
  2. Article first published online: 17 JUN 2010
  3. Accepted manuscript online: 17 JUN 2010 12:00AM EST
  4. Manuscript Accepted: 26 MAY 2010
  5. Manuscript Received: 28 JAN 2010

Funded by

  • Ministero dell'Istruzione, dell'Università e della Ricerca, Rome (PRIN 2005); Associazione Italiana per la Ricerca sul Cancro
  • Milan;
  • Ente Cassa di Risparmio di Firenze
  • Florence;
  • Gruppo Oncologico Chirurgico Cooperativo Italiano, Florence

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article with Supporting Information (HTML) Get PDF (450K)

References

  • 1
    Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. CA Cancer J Clin 2009; 59: 225–49.
    Direct Link:
  • 2
    Longley DB, Allen WL, Johnston PG. Drug resistance, predictive markers and pharmacogenomics in colorectal cancer. Biochim Biophys Acta 2006; 1766: 184–96.
  • 3
    Gill S, Loprinzi CL, Sargent DJ, Thomé SD, Alberts SR, Haller DG, Benedetti J, Francini G, Shepherd LE, Francois Seitz J, Labianca R, Chen W, et al. Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much? J Clin Oncol 2004; 22: 1797–806.
  • 4
    André T, Boni C, Mounedji-Boudiaf L, Navarro M, Tabernero J, Hickish T, Topham C, Zaninelli M, Clingan P, Bridgewater J, Tabah-Fisch I, de Gramont A; Multicenter International Study of Oxaliplatin/5-Fluorouracil/Leucovorin in the Adjuvant Treatment of Colon Cancer (MOSAIC) Investigators. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 2004; 350: 2343–51.
  • 5
    Benson AB, III, Schrag D, Somerfield MR, Cohen AM, Figueredo AT, Flynn PJ, Krzyzanowska MK, Maroun J, McAllister P, Van Cutsem E, Brouwers M, Charette M, et al. American society of clinical oncology recommendations on adjuvant chemotherapy for stage II colon cancer. J Clin Oncol 2004; 22: 3408–19.
  • 6
    NCCN Clinical Practice Guidelines in Oncology. Colon cancer V.I. 2010. Available at: www.nccn.org. Accessed on 30th December, 2009.
  • 7
    International Multicenter Pooled Analysis of B2 Colon Cancer Trial (IMPACT B2). Efficacy of adjuvant fluorouracil and folinic acid in B2 colon cancer. J Clin Oncol 1999; 17: 1356–63.
  • 8
    Sargent D, Sobrero A, Grothey A, O'Connell MJ, Buyse M, Andre T, Zheng Y, Green E, Labianca R, O'Callaghan C, Seitz JF, Francini G, et al. Evidence for cure by adjuvant therapy in colon cancer: observations based on individual patient data from 20,898 patients on 18 randomized trials. J Clin Oncol 2009; 27: 872–7.
  • 9
    Figueredo A, Coombes ME, Mukherjee S. Adjuvant therapy for completely resected stage II colon cancer. Cochrane Database Syst Rev 2008; 3: CD005390.
  • 10
    Koopman M, Venderbosch S, Nagtegaal ID, van Krieken JH, Punt CJ. A review on the use of molecular markers of cytotoxic therapy for colorectal cancer, what have we learned? Eur J Cancer 2009; 45: 935–49.
  • 11
    Locker GY, Hamilton S, Harris J, Jessup JM, Kemeny N, Macdonald JS, Somerfield MR, Hayes DF, Bast RC, Jr. ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. J Clin Oncol 2006; 24: 5313–27.
  • 12
    Kidd EA, Yu J, Li X, Shannon WD, Watson MA, McLeod HL. Variance in the expression of 5-fluorouracil pathway genes in colorectal cancer. Clin Cancer Res 2005; 11: 2612–19.
  • 13
    Walther A, Johnstone E, Swanton C, Midgley R, Tomlinson I, Kerr D. Genetic prognostic and predictive markers in colorectal cancer. Nat Rev Cancer 2009; 9: 489–99.
  • 14
    Sotiriou C, Pusztai L. Gene-expression signatures in breast cancer. N Engl J Med 2009; 360: 790–800.
  • 15
    Popat S, Matakidou A, Houlston RS. Thymidylate synthase expression and prognosis in colorectal cancer: a systematic review and meta-analysis. J Clin Oncol 2004; 22: 529–36.
  • 16
    Salonga D, Danenberg KD, Johnson M, Metzger R, Groshen S, Tsao-Wei DD, Lenz HJ, Leichman CG, Leichman L, Diasio RB, Danenberg PV. Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase. Clin Cancer Res 2000; 6: 1322–7.
  • 17
    Mini E, Biondi C, Morganti M, Napoli C, Mazzoni P, Cianchi F, Tonelli F, Cortesini C, Capaccioli S, Ficari F, Quattrone A, Rossi S, et al. Marked variation of thymidylate synthase and folylpolyglutamate synthetase gene expression in human colorectal tumors. Oncol Res 1999; 11: 437–45.
  • 18
    Morganti M, Ciantelli M, Giglioni B, Putignano AL, Nobili S, Papi L, Landini I, Napoli C, Valanzano R, Cianchi F, Boddi V, Tonelli F, et al. Relationships between promoter polymorphisms in the thymidylate synthase gene and mRNA levels in colorectal cancers. Eur J Cancer 2005; 41: 2176–83.
  • 19
    Koopman M, Venderbosch S, van Tinteren H, Ligtenberg MJ, Nagtegaal I, Van Krieken JH, Punt CJ. Predictive and prognostic markers for the outcome of chemotherapy in advanced colorectal cancer, a retrospective analysis of the phase III randomised CAIRO study. Eur J Cancer 2009; 45: 1999–2006.
  • 20
    Humeniuk R, Menon LG, Mishra PJ, Gorlick R, Sowers R, Rode W, Pizzorno G, Cheng YC, Kemeny N, Bertino JR, Banerjee D. Decreased levels of UMP kinase as a mechanism of fluoropyrimidine resistance. Mol Cancer Ther 2009; 8: 1037–44.
  • 21
    Smorenburg CH, Peters GJ, van Groeningen CJ, Noordhuis P, Smid K, van Riel AM, Dercksen W, Pinedo HM, Giaccone G. Phase II study of tailored chemotherapy for advanced colorectal cancer with either 5-fluouracil and leucovorin or oxaliplatin and irinotecan based on the expression of thymidylate synthase and dihydropyrimidine dehydrogenase. Ann Oncol 2006; 17: 35–42.
  • 22
    Matsuyama R, Togo S, Shimizu D, Momiyama N, Ishikawa T, Ichikawa Y, Endo I, Kunisaki C, Suzuki H, Hayasizaki Y, Shimada H. Predicting 5-fluorouracil chemosensitivity of liver metastases from colorectal cancer using primary tumor specimens: three-gene expression model predicts clinical response. Int J Cancer 2006; 119: 406–13.
    Direct Link:
  • 23
    Gustavsson B, Kaiser C, Carlsson G, Wettergren Y, Odin E, Lindskog EB, Niyikiza C, Ma D. Molecular determinants of efficacy for 5-FU-based treatments in advanced colorectal cancer: mRNA expression for 18 chemotherapy-related genes. Int J Cancer 2009; 124: 1220–6.
    Direct Link:
  • 24
    International Multicentre Pooled Analysis of Colon Cancer Trials (IMPACT) Investigators. Efficacy of adjuvant fluorouracil and folinic acid in colon cancer. Lancet 1995; 345: 939–44.
  • 25
    Canman CE, Lawrence TS, Shewach DS, Tang HY, Maybaum J. Resistance to fluorodeoxyuridine-induced DNA damage and cytotoxicity correlates with an elevation of deoxyuridine triphosphatase activity and failure to accumulate deoxyuridine triphosphate. Cancer Res 1993; 53: 5219–24.
  • 26
    Pugacheva EN, Ivanov AV, Kravchenko JE, Kopnin BP, Levine AJ, Chumakov PM. Novel gain of function activity of p53 mutants: activation of the dUTPase gene expression leading to resistance to 5-fluorouracil. Oncogene 2002; 21: 4595–600.
  • 27
    Ladner RD, Lynch FJ, Groshen S, Xiong YP, Sherrod A, Caradonna SJ, Stoehlmacher J, Lenz HJ. dUTP nucleotidohydrolase isoform expression in normal and neoplastic tissues: association with survival and response to 5-fluorouracil in colorectal cancer. Cancer Res 2000; 60: 3493–503.
  • 28
    Levine AJ, Perry ME, Chang A, Silver A, Dittmer D, Wu M, Welsh D. The 1993 Walter Hubert lecture: the role of the p53 tumour-suppressor gene in tumorigenesis. Br J Cancer 1994; 69: 409–16.
  • 29
    Soussi T, Ishioka C, Claustres M, Béroud C. Locus-specific mutation databases: pitfalls and good practice based on the p53 experience. Nat Rev Cancer 2006; 6: 83–90.
  • 30
    Giovannetti E, Backus HH, Wouters D, Ferreira CG, van Houten VM, Brakenhoff RH, Poupon MF, Azzarello A, Pinedo HM, Peters GJ. Changes in the status of p53 affect drug sensitivity to thymidylate synthase (TS) inhibitors by altering TS levels. Br J Cancer 2007; 96: 769–75.
  • 31
    Bunz F, Hwang PM, Torrance C, Waldman T, Zhang Y, Dillehay L, Williams J, Lengauer C, Kinzler KW, Vogelstein B. Disruption of p53 in human cancer cells alters the responses to therapeutic agents. J Clin Invest 1999; 104: 263–9.
  • 32
    McDermott U, Longley DB, Galligan L, Allen W, Wilson T, Johnston PG. Effect of p53 status and STAT1 on chemotherapy-induced, Fas-mediated apoptosis in colorectal cancer. Cancer Res 2005; 65: 8951–60.
  • 33
    Munro AJ, Lain S, Lane DP. P53 abnormalities and outcomes in colorectal cancer: a systematic review. Br J Cancer 2005; 92: 434–44.
  • 34
    Ahnen DJ, Feigl P, Quan G, Fenoglio-Preiser C, Lovato LC, Bunn PA,Jr, Stemmerman G, Wells JD, Macdonald JS, Meyskens FL, Jr. Ki-ras mutation and p53 overexpression predict the clinical behavior of colorectal cancer: a southwest oncology group study. Cancer Res 1998; 58: 1149–58.
  • 35
    Elsaleh H, Powell B, McCaul K, Grieu F, Grant R, Joseph D, Iacopetta B. P53 alteration and microsatellite instability have predictive value for survival benefit from chemotherapy in stage III colorectal carcinoma. Clin Cancer Res 2001; 7: 1343–9.
  • 36
    Brody JR, Hucl T, Costantino CL, Eshleman JR, Gallmeier E, Zhu H, van der Heijden MS, Winter JM, Wikiewicz AK, Yeo CJ, Kern SE. Limits to thymidylate synthase and TP53 genes as predictive determinants for fluoropyrimidine sensitivity and further evidence for RNA-based toxicity as a major influence. Cancer Res 2009; 69: 984–91.
  • 37
    Hwang PM, Bunz F, Yu J, Rago C, Chan TA, Murphy MP, Kelso GF, Smith RA, Kinzler KW, Vogelstein B. Ferredoxin reductase affects p53-dependent, 5-fluorouracil-induced apoptosis in colorectal cancer cells. Nature Med 2001; 7: 1111–17.
  • 38
    Liu G, Chen X. The ferredoxin reductase gene is regulated by the p53 family and sensitizes cells to oxidative stress-induced apoptosis. Oncogene 2002; 21: 7195–204.
  • 39
    Yu J, Marsh S, Ahluwalia R, McLeod HL. Ferredoxin reductase: pharmacogenomic assessment in colorectal cancer. Cancer Res 2003; 63: 6170–3.
  • 40
    Ichikawa W, Ooyama A, Toda E, Sugimoto Y, Oka T, Takahashi T, Shimizu M, Sasaki Y, Hirayama R. Gene expression of ferredoxin reductase predicts outcome in patients with metastatic colorectal cancer treated by 5-fluorouracil plus leucovorin. Cancer Chemother Pharmacol 2006; 58: 794–801.
  • 41
    Sarris M, Lee CS. nm23 protein expression in colorectal carcinoma metastasis in regional lymph nodes and the liver. Eur J Surg Oncol 2001; 27: 170–4.
  • 42
    Soliani P, Ziegler S, Romani A, Corcione L, Campanini N, Dell′Abate P, Del Rio P, Sianesi M. Prognostic significance of nm23 gene product expression in patients with colorectal carcinoma treated with radical intent. Oncol Rep 2004; 11: 1193–200.
  • 43
    Dursun A, Akyürek N, Günel N, Yamaç D. Prognostic implication of nm23-H1 expression in colorectal carcinomas. Pathology 2002; 34: 427–32.
  • 44
    Berney CR, Yang JL, Fisher RJ, Russell PJ, Crowe PJ. Overexpression of nm23 protein assessed by color video image analysis in metastatic colorectal cancer: correlation with reduced patient survival. World J Surg 1998; 22: 484–90.
  • 45
    Brenner AS, Thebo JS, Senagore AJ, Duepree HJ, Gramlich T, Ormsby A, Lavery IC, Fazio VW. Analysis of both NM23-h1 and NM23-H2 expression identifies “at-risk” patients with colorectal cancer. Ann Surg 2003; 69: 203–8.
  • 46
    Johnston PG, Fisher ER, Rockette HE, Fisher B, Wolmark N, Drake JC, Chabner BA, Allegra CJ. The role of thymidylate synthase expression in prognosis and outcome of adjuvant chemotherapy in patients with rectal cancer. J Clin Oncol 1994; 12: 2640–7.
  • 47
    Edler D, Glimelius B, Hallström M, Jakobsen A, Johnston PG, Magnusson I, Ragnhammar P, Blomgren H. Thymidylate synthase expression in colorectal cancer: a prognostic and predictive marker of benefit from adjuvant fluorouracil-based chemotherapy. J Clin Oncol 2002; 20: 1721–8.
  • 48
    Takenoue T, Nagawa H, Matsuda K, Fujii S, Nita ME, Hatano K, Kitayama J, Tsuruo T, Muto T. Relation between thymidylate synthase expression and survival in colon carcinoma, and determination of appropriate application of 5-fluorouracil by immunohistochemical method. Ann Surg Oncol 2000; 7: 193–8.
  • 49
    Yamachika T, Nakanishi H, Inada K, Tsukamoto T, Kato T, Fukushima M, Inoue M, Tatematsu M. A new prognostic factor for colorectal carcinoma, thymidylate synthase, and its therapeutic significance. Cancer 1998; 82: 70–7.
    Direct Link:
  • 50
    Fukushima M, Fujioka A, Uchida J, Nakagawa F, Takechi T. Thymidylate synthase (TS) and ribonucleotide reductase (RNR) may be involved in acquired resistance to 5-fluorouracil (5-FU) in human cancer xenografts in vivo. Eur J Cancer 2001; 37: 1681–7.
  • 51
    Kubota T, Watanabe M, Otani Y, Kitajima M, Fukushiuma M. Different pathways of 5-fluorouracil metabolism after continuous venous or bolus injection in patients with colon carcinoma: possible predictive value of thymidylate synthetase mRNA and ribonucleotide reductase for 5-fluorouracil sensitivity. Anticancer Res 2002; 22: 3537–40.
View Full Article with Supporting Information (HTML) Get PDF (450K)